HIGHER: Nexstar (NXST) and Tribune Media (TRCO), up 1% and 10%, respectively, after Nexstar announced a deal to acquire all outstanding shares of Tribune for $46.50 per share in a cash transaction that is valued at $6.4B... Tesaro (TSRO), up 59% after GlaxoSmithKline (GSK) announced a definitive agreement to acquire Tesaro for $75 per share. Shares of Tesaro competitor Clovis Oncology (CLVS) are up 28% in sympathy... New Age Beverages (NBEV), up 16% after announcing the signing of an agreement to acquire Morinda Holdings for $85M... Roku (ROKU), up 6% after DA Davidson analyst Tom Forte upgraded the stock to Buy from Neutral, stating that the stock is "attractive" following reports of a 90-day U.S.-China trade truce reached this weekend given that all of the company's products are manufactured in China. LOWER: GlaxoSmithKline (GSK), down 7% after announcing it will acquire Tesaro for $75 per share... Bluebird Bio (BLUE), down 7% after the company and Celgene (CELG) announced initial data from the ongoing Phase 1 clinical study of bb21217, an investigational next-generation anti-BCMA CAR T cell therapy being studied in patients with relapsed/refractory multiple myeloma. Piper Jaffray analyst Danielle Brill also said that she thinks Global Blood Therapeutics (GBT) will benefit from Bluebird Bio's safety setback with its LentiGlobin gene therapy for SCD... Ocular Therapeutix (OCUL), down 8% after announcing FDA approval of Dextenza.
